{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:28:32Z","timestamp":1776702512785,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106942","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:10:35Z","timestamp":1774959035000},"page":"106942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed\/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study"],"prefix":"10.1016","volume":"11","author":[{"given":"J.","family":"Trotman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-7175","authenticated-orcid":false,"given":"F.","family":"Bijou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"\u0160\u00e1lek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dumartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.106942_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106942_bib2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.esmoop.2026.106942_bib3","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106942_bib4","article-title":"Brukinsa: Prescribing information","year":"2025","journal-title":"BeiGene"},{"key":"10.1016\/j.esmoop.2026.106942_bib5","series-title":"Brukinsa: Summary of product characteristics","year":"2024"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106942_bib6","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.3390\/cancers12113246","article-title":"Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis","volume":"12","author":"Italiano","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106942_bib7","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs \u2013 twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106942_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106942_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106942_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11912-025-01667-1","article-title":"The Growth Modulation Index (GMI) as an efficacy outcome in cancer clinical trials: a scoping review with suggested reporting guidelines","volume":"27","author":"Trin","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106942_bib12","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab-and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106942_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mds470","article-title":"Growth Modulation Index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy","volume":"24","author":"Penel","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106942_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101616","article-title":"Evaluation of the relevance of the Growth Modulation Index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens","volume":"8","author":"du Rusquec","year":"2023","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106942_bib15","article-title":"MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:32:00Z","timestamp":1776699120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008847"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106942","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed\/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106942"}}